ATE442356T1 - 1-essigsäureindolderivate mit pgd2- antagonistischer wirkung - Google Patents
1-essigsäureindolderivate mit pgd2- antagonistischer wirkungInfo
- Publication number
- ATE442356T1 ATE442356T1 AT06726357T AT06726357T ATE442356T1 AT E442356 T1 ATE442356 T1 AT E442356T1 AT 06726357 T AT06726357 T AT 06726357T AT 06726357 T AT06726357 T AT 06726357T AT E442356 T1 ATE442356 T1 AT E442356T1
- Authority
- AT
- Austria
- Prior art keywords
- acetic acid
- antagonistic effect
- pgd2
- alkyl
- indol derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0505048.9A GB0505048D0 (en) | 2005-03-11 | 2005-03-11 | Compounds with PGD antagonist activity |
| PCT/GB2006/000851 WO2006095183A1 (en) | 2005-03-11 | 2006-03-10 | 1-acetic acid-indole derivatives with pgd2 antagonist activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE442356T1 true ATE442356T1 (de) | 2009-09-15 |
Family
ID=34508918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06726357T ATE442356T1 (de) | 2005-03-11 | 2006-03-10 | 1-essigsäureindolderivate mit pgd2- antagonistischer wirkung |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8044088B2 (de) |
| EP (1) | EP1856045B1 (de) |
| JP (1) | JP2008532990A (de) |
| KR (1) | KR20070116633A (de) |
| CN (1) | CN101166721A (de) |
| AT (1) | ATE442356T1 (de) |
| AU (1) | AU2006221784A1 (de) |
| BR (1) | BRPI0608732A2 (de) |
| CA (1) | CA2601980A1 (de) |
| CY (1) | CY1109532T1 (de) |
| DE (1) | DE602006009080D1 (de) |
| DK (1) | DK1856045T3 (de) |
| ES (1) | ES2333161T3 (de) |
| GB (1) | GB0505048D0 (de) |
| HK (1) | HK1109628A1 (de) |
| HR (1) | HRP20090654T1 (de) |
| IL (1) | IL185844A0 (de) |
| MX (1) | MX2007011091A (de) |
| NO (1) | NO20074641L (de) |
| NZ (1) | NZ561747A (de) |
| PL (1) | PL1856045T3 (de) |
| PT (1) | PT1856045E (de) |
| RS (1) | RS51016B (de) |
| RU (1) | RU2007134456A (de) |
| SI (1) | SI1856045T1 (de) |
| WO (1) | WO2006095183A1 (de) |
| ZA (1) | ZA200708159B (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| PL2037967T3 (pl) | 2006-06-16 | 2017-07-31 | The Trustees Of The University Of Pennsylvania | Antagoniści receptora prostaglandyny D2 w leczeniu łysienia androgenowego |
| JP5270542B2 (ja) * | 2006-07-22 | 2013-08-21 | オキサジェン リミテッド | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 |
| JP5220013B2 (ja) | 2006-08-07 | 2013-06-26 | アクテリオン ファーマシューティカルズ リミテッド | （３−アミノ−１，２，３，４−テトラヒドロ−９ｈ−カルバゾール−９−イル）−酢酸誘導体 |
| GB0722216D0 (en) * | 2007-11-13 | 2007-12-27 | Oxagen Ltd | Use of crth2 antagonist compounds |
| GB0722203D0 (en) * | 2007-11-13 | 2007-12-19 | Oxagen Ltd | Use of CRTH2 antagonist compounds |
| EP2229358B1 (de) * | 2007-12-14 | 2011-03-23 | Pulmagen Therapeutics (Asthma) Limited | Indole und ihre therapeutische verwendung |
| ES2442717T3 (es) | 2008-01-18 | 2014-02-13 | Atopix Therapeutics Limited | Compuestos que tienen actividad antagonista de CRTH2 |
| US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| WO2009093029A1 (en) | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
| US8470594B2 (en) * | 2008-04-15 | 2013-06-25 | President And Fellows Of Harvard College | Methods for identifying agents that affect the survival of motor neurons |
| US9180114B2 (en) | 2008-11-26 | 2015-11-10 | President And Fellows Of Harvard College | Neurodegenerative diseases and methods of modeling |
| EP2401269B1 (de) * | 2009-02-24 | 2014-01-29 | Merck Sharp & Dohme Corp. | Indolderivate als crth2-rezeptor-antagonisten |
| MA34094B1 (fr) | 2010-03-22 | 2013-03-05 | Actelion Pharmaceuticals Ltd | Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2 |
| GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| MX338516B (es) | 2011-04-14 | 2016-04-20 | Actelion Pharmaceuticals Ltd | Derivados de acido 7- (heteroaril-amino) -6, 7, 8, 9- tetrahidropirido[1,2-a] indol acetico y sus usos como modulador del receptor de prostaglandina. |
| PL2781508T3 (pl) * | 2011-11-17 | 2019-06-28 | Kbp Biosciences Co., Ltd. | Związki pierścieniowe o układzie skondensowanych pierścieni zawierające azot do zastosowania jako antagonisty CRTH2 |
| GB201121557D0 (en) | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
| SG11201402796SA (en) | 2011-12-16 | 2014-06-27 | Atopix Therapeutics Ltd | Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
| WO2014066568A1 (en) | 2012-10-24 | 2014-05-01 | Winthrop-University Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
| KR102116978B1 (ko) | 2013-10-07 | 2020-05-29 | 삼성전자 주식회사 | 그래핀 소자 및 그 제조 방법 |
| GB201322273D0 (en) * | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
| MY179356A (en) | 2014-03-17 | 2020-11-05 | Idorsia Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| GB201407807D0 (en) * | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| US20180021302A1 (en) | 2015-02-13 | 2018-01-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
| US20200078351A1 (en) | 2015-07-30 | 2020-03-12 | The Trustees Of The University Of Pennsylvania | Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2 |
| MX2018003202A (es) | 2015-09-15 | 2018-06-08 | Idorsia Pharmaceuticals Ltd | Formas cristalinas. |
| JP2020533595A (ja) | 2017-09-13 | 2020-11-19 | プロジェニティ， インコーポレイテッド | 子癇前症バイオマーカならびに関連するシステムおよび方法 |
| CN109180691B (zh) * | 2018-08-24 | 2020-07-10 | 武汉大学 | 一种c3-芳香型吡咯并吲哚类生物碱及其合成方法 |
| EP4070113A4 (de) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | Beurteilung von präeklampsie unter verwendung von tests für freien und dissoziierten plazentalen wachstumsfaktor |
| CN113425714B (zh) * | 2021-08-04 | 2022-04-26 | 华南师范大学 | 吲哚乙酸在制备防治慢性阻塞性肺病药物中的应用 |
| CN114870018A (zh) * | 2022-05-12 | 2022-08-09 | 江南大学 | 炎症小体nlrp3抑制剂通过抑制神经系统炎症在制备治疗阿尔茨海默症药物中的应用 |
| WO2024192765A1 (en) * | 2023-03-23 | 2024-09-26 | Brown University | First in class use of the crth2 antagonist in treating neuromyelitis optica spectrum disorder (nmosd) and relevant autoimmune cns disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641800A (en) | 1994-07-21 | 1997-06-24 | Eli Lilly And Company | 1H-indole-1-functional sPLA2 inhibitors |
| MXPA02003122A (es) | 1998-03-31 | 2004-04-21 | Inst For Pharm Discovery Inc | Acidos indolalcanoicos substituidos. |
| AU2003231509A1 (en) | 2002-05-16 | 2003-12-02 | Shionogi And Co., Ltd. | Compound exhibiting pgd 2 receptor antagonism |
| TW200307542A (en) * | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) * | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| SE0302232D0 (sv) * | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| SE0303180D0 (sv) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| GB0504150D0 (en) | 2005-03-01 | 2005-04-06 | Oxagen Ltd | Microcrystalline material |
| JP5270542B2 (ja) | 2006-07-22 | 2013-08-21 | オキサジェン リミテッド | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 |
| EP2229358B1 (de) | 2007-12-14 | 2011-03-23 | Pulmagen Therapeutics (Asthma) Limited | Indole und ihre therapeutische verwendung |
| US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| WO2009093029A1 (en) | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
| JP2011509990A (ja) | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 |
-
2005
- 2005-03-11 GB GBGB0505048.9A patent/GB0505048D0/en not_active Ceased
-
2006
- 2006-03-10 ES ES06726357T patent/ES2333161T3/es active Active
- 2006-03-10 KR KR1020077023379A patent/KR20070116633A/ko not_active Application Discontinuation
- 2006-03-10 BR BRPI0608732A patent/BRPI0608732A2/pt not_active IP Right Cessation
- 2006-03-10 EP EP06726357A patent/EP1856045B1/de active Active
- 2006-03-10 MX MX2007011091A patent/MX2007011091A/es active IP Right Grant
- 2006-03-10 DK DK06726357T patent/DK1856045T3/da active
- 2006-03-10 CN CNA2006800139287A patent/CN101166721A/zh active Pending
- 2006-03-10 SI SI200630491T patent/SI1856045T1/sl unknown
- 2006-03-10 PT PT06726357T patent/PT1856045E/pt unknown
- 2006-03-10 US US11/908,401 patent/US8044088B2/en not_active Expired - Fee Related
- 2006-03-10 WO PCT/GB2006/000851 patent/WO2006095183A1/en active Application Filing
- 2006-03-10 PL PL06726357T patent/PL1856045T3/pl unknown
- 2006-03-10 AT AT06726357T patent/ATE442356T1/de active
- 2006-03-10 JP JP2008500270A patent/JP2008532990A/ja active Pending
- 2006-03-10 RU RU2007134456/04A patent/RU2007134456A/ru not_active Application Discontinuation
- 2006-03-10 RS RSP-2009/0534A patent/RS51016B/sr unknown
- 2006-03-10 NZ NZ561747A patent/NZ561747A/xx not_active IP Right Cessation
- 2006-03-10 DE DE602006009080T patent/DE602006009080D1/de active Active
- 2006-03-10 AU AU2006221784A patent/AU2006221784A1/en not_active Withdrawn
- 2006-03-10 CA CA002601980A patent/CA2601980A1/en not_active Abandoned
-
2007
- 2007-09-10 IL IL185844A patent/IL185844A0/en unknown
- 2007-09-12 NO NO20074641A patent/NO20074641L/no not_active Application Discontinuation
- 2007-09-21 ZA ZA200708159A patent/ZA200708159B/xx unknown
-
2008
- 2008-04-08 HK HK08103897.0A patent/HK1109628A1/xx not_active IP Right Cessation
-
2009
- 2009-12-08 CY CY20091101280T patent/CY1109532T1/el unknown
- 2009-12-09 HR HR20090654T patent/HRP20090654T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101166721A (zh) | 2008-04-23 |
| EP1856045A1 (de) | 2007-11-21 |
| EP1856045B1 (de) | 2009-09-09 |
| IL185844A0 (en) | 2008-01-06 |
| NZ561747A (en) | 2010-03-26 |
| WO2006095183A1 (en) | 2006-09-14 |
| HRP20090654T1 (hr) | 2010-01-31 |
| KR20070116633A (ko) | 2007-12-10 |
| ES2333161T3 (es) | 2010-02-17 |
| CA2601980A1 (en) | 2006-09-14 |
| US8044088B2 (en) | 2011-10-25 |
| US20100330077A1 (en) | 2010-12-30 |
| DK1856045T3 (da) | 2010-01-04 |
| PT1856045E (pt) | 2009-12-09 |
| JP2008532990A (ja) | 2008-08-21 |
| RS51016B (sr) | 2010-10-31 |
| AU2006221784A1 (en) | 2006-09-14 |
| DE602006009080D1 (de) | 2009-10-22 |
| NO20074641L (no) | 2007-11-01 |
| HK1109628A1 (en) | 2008-06-13 |
| RU2007134456A (ru) | 2009-04-20 |
| CY1109532T1 (el) | 2014-08-13 |
| ZA200708159B (en) | 2009-11-25 |
| PL1856045T3 (pl) | 2010-02-26 |
| SI1856045T1 (sl) | 2010-01-29 |
| GB0505048D0 (en) | 2005-04-20 |
| BRPI0608732A2 (pt) | 2016-11-08 |
| MX2007011091A (es) | 2007-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE442356T1 (de) | 1-essigsäureindolderivate mit pgd2- antagonistischer wirkung | |
| PE20091005A1 (es) | N-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas | |
| CY1122863T1 (el) | Φαρμακευτικη συνθεση που περιεχει γλυκοπυρρολικο και εναν αγωνιστη βητα2 αδρενοϋποδοχεα | |
| EA200500304A1 (ru) | Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний | |
| HRP20070430T3 (en) | (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity | |
| NO20070532L (no) | Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer | |
| NO20071617L (no) | Indozolonderivater som 11B-HSD1-inhibitorer | |
| GB0510584D0 (en) | Organic compounds | |
| ATE553106T1 (de) | Heteroarylpyrrolopyridinone als kinaseinhibitoren | |
| RS52349B (en) | 5-SUBSTITUTED HINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | |
| NO20080738L (no) | Fremgangsmater for neurobeskyttelse | |
| CY1109883T1 (el) | Υδατικα συγκεντρωματα δραστικων ουσιων με ζιζανιοκτονα δραση | |
| NO20075734L (no) | Tiofenforbindelser og trombopoietin reseptoractivatorer | |
| ATE449776T1 (de) | Pyrroloä2,3-cüpyridinderivate | |
| EA200700997A1 (ru) | 2,5- и 2,6-дизамещенные аналоги бензазола, полезные в качестве ингибиторов протеинкиназ | |
| RU2010115337A (ru) | Трициклические гетероциклические производные | |
| EA200801366A1 (ru) | Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина | |
| ATE466007T1 (de) | 5-substituierte indol-2-carbonsäureamidderivate | |
| NO20071319L (no) | Fremgangsmate for fremstilling av isotiazolderivater. | |
| CY1112638T1 (el) | Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον | |
| CO6321159A2 (es) | Compuestos pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias | |
| NO20090332L (no) | 4-amino-3-arylamino-6-arylpyrazol[3,4-D]pyrimidinderivater, fremgangsmater for deres fremstilling og dere anvendelse som antivirale midler | |
| EA200700322A1 (ru) | Оксазолидиноны, содержащие оксиндолы, в качестве антибактериальных агентов | |
| ATE465151T1 (de) | 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren | |
| UA97957C2 (ru) | 2-{5-фтор-2-метил-3-[2-(фенилсульфонил)бензил]-1н-индол-1-ил}уксусная кислота и ее производные, их применение для лечения заболеваний, опосредствованных действием pgd2 на рецептор crth2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1856045 Country of ref document: EP |